Enveric Biosciences, Inc.
ENVB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $337 | $408 | $435 | $682 |
| Gross Profit | -$337 | -$408 | -$435 | -$682 |
| % Margin | – | – | – | – |
| R&D Expenses | $2,841 | $7,252 | $8,028 | $4,789 |
| G&A Expenses | $0 | $8,852 | $0 | $0 |
| SG&A Expenses | $6,454 | $8,788 | $11,498 | $20,474 |
| Sales & Mktg Exp. | $0 | -$64 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $9,295 | $16,040 | $19,526 | $25,263 |
| Operating Income | -$9,632 | -$16,448 | -$19,961 | -$25,945 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $66 | -$814 | $4 | -$30,487 |
| Pre-Tax Income | -$9,566 | -$17,263 | -$19,957 | -$56,432 |
| Tax Expense | $9 | $29 | -$1,486 | -$7,455 |
| Net Income | -$9,575 | -$17 | -$18,504 | -$48,977 |
| % Margin | – | – | – | – |
| EPS | -228.48 | -97.08 | -87.72 | -1,244.28 |
| % Growth | -135.4% | -10.7% | 93% | – |
| EPS Diluted | -228.48 | -97.08 | -156 | -1,244.28 |
| Weighted Avg Shares Out | 42 | 211 | 211 | 39 |
| Weighted Avg Shares Out Dil | 42 | 180 | 173 | 39 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $4 | $5 | $10 |
| Depreciation & Amortization | $337 | $408 | $435 | $682 |
| EBITDA | -$9,229 | -$16,855 | -$19,517 | -$55,740 |
| % Margin | – | – | – | – |